Indium In 111 Autologous leukocytes are labelled by the radiopharmaceutical oxyquinoline before being given intravenously. These cells move to the location of the infection or inflammation and can help with the diagnosis.

Indium In-111 oxyquinoline Uses:

• Diagnostic imaging:

  • It is used in the diagnosis of inflammatory/infective processes in patients in whom the diagnosis fails or is doubtful with other means like ultrasonography and computed tomography.
  • It labels autologous leukocytes with radiolabeled indium which migrate to the site of infection and inflammation and are detected.

Indium In 111 dose in adults:

Indium In 111 Dose in Diagnostic imaging:

• Adults:

  • IV (based on 70 kg patient):
    • 200 to 500 microCi (7.4 to 18.5 MBq)

Use in Children:

It is not indicated for use in children.

Pregnancy Risk Factor C

• Animal reproduction studies have not included any study of the drug.
• Women who elect to have an elective procedure performed on a female body may be advised that it is done within ten days after the menstrual cycle begins.

Use during breastfeeding:

• Breast milk contains the drug.
• The manufacturer suggests that breastmilk should be stopped and replaced with formula milk until radioactivity is gone.

Dose in Kidney Disease:

There are no dosage adjustments provided in the manufacturer's labeling.

Dose in Liver disease:

There are no dosage adjustments provided in the manufacturer's labeling.

Indium In 111 Side effects:

• Dermatologic:

  • Urticaria

• Hypersensitivity:

  • Hypersensitivity reactions

• Miscellaneous:

  • Fever

Contraindications to Indium In-111 oxyquinoline:

The manufacturer's labeling does not contain any contraindications.

Warnings and precautions

• Leukopenia:

  • Patients with leukopenia should not be labeled by autologous leukocytes. This is because there are a small number of leukocytes which could cause a false-negative result.

Monitoring parameters:

None mentioned.

How to administer Indium In-111 oxyquinoline?

• The drug should not be administered directly as an IV injection. Indium In-111 oxyquinoline labeled autologous leukocytes may be administered intravenously.
• The patient may undergo imaging after 24 hours of the drug administration.
• Since it is a radiopharmaceutical agent, it requires proper handling and disposal.
• During handling and administration, wear waterproof gloves.

Mechanism of action of Indium In-111 oxyquinoline:

It can be used to detect inflammation processes, such as abscesses and other infections, by creating radiolabeled autonomous leukocytes.

Distribution:

• 30% spleen;
• 30% liver;
• 4% to 7.5% pulmonary (Typically, radioactivity is only noticeable for around 4 hours following injection);
• The remainder is distributed throughout the body and red marrow

Half-life elimination:

• Physical half-life: 67.2 hours

Excretion:

• Urine and feces (<1%), mainly through decay to stable cadmium